Median Technologies (4ZG) Price & Analysis

0 Followers

4ZG Stock Chart & Stats

€3.22

€0.01(0.25%)

At close: Jan 08 4:00 PM EST

€3.22

€0.01(0.25%)

Day’s Range― - ―

52-Week Range€1.77 - €6.42

Previous CloseN/A

Volume0.00

Average Volume (3M)81.00

Market Cap

€202.66M

Enterprise Value€180.92

Total Cash (Recent Filing)€18.41M

Total Debt (Recent Filing)€21.76M

Price to Earnings (P/E)―

Beta0.42

Next Earnings

Oct 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.15

Shares Outstanding49,048,060

10 Day Avg. Volume223

30 Day Avg. Volume81

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)-4.95

Price to Sales (P/S)7.45

P/FCF Ratio-9.58

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.44

Revenue Forecast (FY)€25.43M

Bulls Say, Bears Say

Bulls Say

Revenue Growth MomentumSustained revenue growth into 2025 (21.5%) indicates expanding demand for the company’s imaging services and software from clinical trials and customers. Over a 2–6 month horizon this momentum supports scale economics and increases probability that fixed costs can be better absorbed as throughput grows.

Diversified Service + Software ModelEarnings are driven by both per-trial imaging services and recurring/software licensing, providing multiple revenue levers. This hybrid model creates durable cash flow optionality: services win near-term contracts while software/subscriptions can build recurring, higher-margin revenue as product adoption and platform penetration increase.

Specialized Oncology AI ExpertiseDomain-specific AI and radiomics for oncology is a high-barrier niche requiring clinical validation and regulatory know-how. This specialization fosters stickiness with biopharma and clinical customers, supports differentiated product positioning, and aligns with structural growth in oncology trials and imaging-driven endpoints.

Bears Say

Negative Equity & Weak Capital BasePersistent negative equity materially reduces financial flexibility and increases the company’s reliance on external financing. Over months this raises dilution and refinancing risk, limiting capacity to invest in product development or scale commercial operations without securing new capital under potentially unfavorable terms.

Consistent Operating Cash BurnRepeated negative operating cash flow indicates core operations are not self-funding, necessitating ongoing capital injections. This structural cash burn constrains strategic options, impedes long-term R&D or commercial scaling unless offset by reliable external funding or a rapid shift to positive free cash generation.

Unprofitable Core Operations And MarginsNegative gross profit and very large net losses show the core business economics are currently unfavorable, implying pricing, cost structure, or mix issues. Without structural improvements to unit economics or higher-margin recurring revenue, profitability will remain a multi-quarter risk and hinder sustainable margin recovery.

Median Technologies News

Median Technologies strikes global Canon partnership to scale AI lung cancer screening

Median Technologies ( ($FR:ALMDT) ) has issued an announcement. Median Technologies has signed a global strategic commercial partnership...

6d ago

Median Technologies strengthens finances as eyonis lung cancer AI wins U.S. and EU approval

Median Technologies ( ($FR:ALMDT) ) has shared an update. Median Technologies, a specialist in AI-based medical imaging software...

14d ago

4ZG FAQ

What was Median Technologies’s price range in the past 12 months?

Median Technologies lowest stock price was €1.77 and its highest was €6.42 in the past 12 months.

What is Median Technologies’s market cap?

Median Technologies’s market cap is €202.66M.

When is Median Technologies’s upcoming earnings report date?

Median Technologies’s upcoming earnings report date is Oct 15, 2026 which is in 71 days.

How were Median Technologies’s earnings last quarter?

Median Technologies released its earnings results on Apr 23, 2026. The company reported -€0.677 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Median Technologies overvalued?

According to Wall Street analysts Median Technologies’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Median Technologies pay dividends?

Median Technologies does not currently pay dividends.

What is Median Technologies’s EPS estimate?

Median Technologies’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Median Technologies have?

Median Technologies has 49,048,060 shares outstanding.

What happened to Median Technologies’s price movement after its last earnings report?

Median Technologies reported an EPS of -€0.677 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.212%.

Which hedge fund is a major shareholder of Median Technologies?

Currently, no hedge funds are holding shares in DE:4ZG

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Median Technologies

Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.